Review: Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy

Neuropathology and Applied Neurobiology

Volumn 39, Issue 6, 2013, Pages 593-611

  Carare, R O ^a   Hawkes, C A ^a   Jeffrey, M ^b   Kalaria, R N ^c   Weller, R O ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b VETERINARY LABORATORIES AGENCY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; CADASIL; Cerebral amyloid angiopathy; Prions; Protein elimination failure angiopathy (PEFA); Therapy

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; DEXTRAN; LAMININ; OVALBUMIN; PRION PROTEIN;

AGING; ALZHEIMER DISEASE; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; AUTOSOMAL DOMINANT DISORDER; BASEMENT MEMBRANE; BLOOD VESSEL WALL; BRAIN ARTERY; BRAIN BLOOD VESSEL; BRAIN CAPILLARY; BRAIN DISEASE; BRAIN INFARCTION; BRAIN TISSUE; CADASIL; CONFOCAL MICROSCOPY; DEGENERATIVE DISEASE; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; LYMPHATIC DRAINAGE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ELIMINATION FAILURE ANGIOPATHY; PROTEIN LOCALIZATION; PROTEIN SECRETION; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ALZHEIMER'S DISEASE; CADASIL; CEREBRAL AMYLOID ANGIOPATHY; PRIONS; PROTEIN ELIMINATION FAILURE ANGIOPATHY (PEFA); THERAPY;

AMYLOIDOGENIC PROTEINS; BRAIN; CADASIL; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL ARTERIAL DISEASES; CEREBROVASCULAR CIRCULATION; HUMANS; NEURODEGENERATIVE DISEASES; PRION DISEASES;

EID: 84882240842     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12042     Document Type: Article

References (86)

1. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008; 18: 253-266
2. Davson H, Welch K, Segal MB. Physiology and Pathophysiology of the Cerebrospinal Fluid. Edinburgh: Churchill Livingstone, 1987
3. Johnston M, Zakharov A, Papaiconomou C, Salmasi G, Armstrong D. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 2004; 1: 2-15
4. Kida S, Pantazis A, Weller RO. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol 1993; 19: 480-488
5. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 1985; 326: 47-63
6. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med 2012; 15: 147ra11
7. Szentistvanyi I, Patlak CS, Ellis RA, Cserr HF. Drainage of interstitial fluid from different regions of rat brain. Am J Physiol 1984; 246: F835-844
8. Carare RO, Bernardes-Silva M, Newman TA, Page AM, Nicoll JAR, Perry VH, Weller RO. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries. Significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol Appl Neurobiol 2008; 34: 131-144
9. Weller RO, Galea I, Carare RO, Minagar A. Pathophysiology of the lymphatic drainage of the central nervous system: implications for pathogenesis and therapy of multiple sclerosis. Pathophysiology 2010; 17: 295-306
10. Kaminski M, Bechmann I, Pohland M, Kiwit J, Nitsch R, Glumm J. Migration of monocytes after intracerebral injection at entorhinal cortex lesion site. J Leukoc Biol 2012; 92: 31-39
11. Teeling JL, Carare RO, Glennie MJ, Perry VH. Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction. Acta Neuropathol (Berl) 2012; 124: 479-490
12. Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol (Berl) 2009; 117: 1-14
13. Ball KK, Cruz NF, Mrak RE, Dienel GA. Trafficking of glucose, lactate, and amyloid-beta from the inferior colliculus through perivascular routes. J Cereb Blood Flow Metab 2010; 30: 162-176. Epub 2009/10/02
14. Hawkes CA, Hartig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol (Berl) 2011; 121: 431-443
15. Barua NU, Bienemann AS, Hesketh S, Wyatt MJ, Castrique E, Love S, Gill SS. Intrastriatal convection-enhanced delivery results in widespread perivascular distribution in a pre-clinical model. Fluids Barriers CNS 2012; 9: 2
16. Zhang ET, Richards HK, Kida S, Weller RO. Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain. Acta Neuropathol (Berl) 1992; 83: 233-239
17. Schley D, Carare-Nnadi R, Please CP, Perry VH, Weller RO. Mechanisms to explain the reverse perivascular transport of solutes out of the brain. J Theor Biol 2006; 238: 962-974
18. Wang P, Olbricht WL. Fluid mechanics in the perivascular space. J Theor Biol 2011; 274: 52-57
19. Beach TG, Potter PE, Kuo YM, Emmerling MR, Durham RA, Webster SD, Walker DG, Sue LI, Scott S, Layne KJ, Roher AE. Cholinergic deafferentation of the rabbit cortex: a new animal model of Abeta deposition. Neurosci Lett 2000; 283: 9-12
20. Weller RO, Love S, Nicoll JAR. Elimination of Aβ from the brain, its failure in Alzheimer's disease and implications for therapy. In Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd edn. Eds DW Dickson, RO Weller. Oxford, UK: Wiley-Blackwell, 2011; 97-101
21. Wiese S, Karus M, Faissner A. Astrocytes as a source for extracellular matrix molecules and cytokines. Front Pharmacol 2012; 3: 120
22. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rostagno A, Ghiso J. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol (Berl) 2009; 118: 115-130
23. Herzig MC, Van Nostrand WE, Jucker M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 2006; 16: 40-54
24. Frackowiak J, Potempska A, LeVine H, Haske T, Dickson D, Mazur-Kolecka B. Extracellular deposits of A beta produced in cultures of Alzheimer disease brain vascular smooth muscle cells. J Neuropathol Exp Neurol 2005; 64: 82-90
25. Rosales XQ, Gastier-Foster JM, Lewis S, Vinod M, Thrush DL, Astbury C, Pyatt R, Reshmi S, Sahenk Z, Mendell JR. Novel diagnostic features of dysferlinopathies. Muscle Nerve 2010; 42: 14-21
26. Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JA, Carare RO. Disruption of arterial perivascular drainage of amyloid-beta from the brains of mice expressing the human APOE epsilon4 allele. PLoS ONE 2012; 7: e41636
27. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008; 18: 240-252
28. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol (Berl) 2009; 118: 103-113
29. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-beta(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489-1499
30. Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 2003; 361: 1957-1958
31. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006; 16: 30-39
32. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 2009; 106: 1261-1266
33. Weller RO, Boche D, Nicoll JA. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol (Berl) 2009; 118: 87-102
34. Roher AE, Garami Z, Tyas SL, Maarouf CL, Kokjohn TA, Belohlavek M, Vedders LJ, Connor D, Sabbagh MN, Beach TG, Emmerling MR. Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease. Alzheimers Dement 2011; 7: 445-455
35. Candiello J, Cole GJ, Halfter W. Age-dependent changes in the structure, composition and biophysical properties of a human basement membrane. Matrix Biol 2010; 29: 402-410
36. Berzin TM, Zipser BD, Rafii MS, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, Fallon JR, Stopa EG. Agrin and microvascular damage in Alzheimer's disease. Neurobiol Aging 2000; 21: 349-355
37. Uspenskaia O, Liebetrau M, Herms J, Danek A, Hamann GF. Aging is associated with increased collagen type IV accumulation in the basal lamina of human cerebral microvessels. BMC Neurosci 2004; 5: 37
38. Kiuchi Y, Isobe Y, Fukushima K. Type IV collagen prevents amyloid beta-protein fibril formation. Life Sci 2002; 70: 1555-1564
39. Bronfman FC, Garrido J, Alvarez A, Morgan C, Inestrosa NC. Laminin inhibits amyloid-beta-peptide fibrillation. Neurosci Lett 1996; 218: 201-203
40. Castillo GM, Lukito W, Peskind E, Raskind M, Kirschner DA, Yee AG, Snow AD. Laminin inhibition of beta-amyloid protein (Abeta) fibrillogenesis and identification of an Abeta binding site localized to the globular domain repeats on the laminin a chain. J Neurosci Res 2000; 62: 451-462
41. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J Neurochem 1997; 69: 2452-2465
42. Wyss Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol 2000; 156: 139-150
43. Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A, Arai M, Schreier WA, Morgan DG. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 1994; 12: 219-234
44. Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, Perry RT, Bassett SS, Chase G, Meyers D, Albert MS, Tanzi R. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997; 48: 139-147
45. Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci 2005; 25: 2803-2810
46. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, Kolsch H, Del Tredici K, Attems J, Ghebremedhin E. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol (Berl) 2010; 120: 169-183
47. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 2007; 11: 1227-1238
48. Kalaria RN, Premkumar DR, Pax AB, Cohen DL, Lieberburg I. Production and increased detection of amyloid beta protein and amyloidogenic fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer's disease. Brain Res Mol Brain Res 1996; 35: 58-68
49. Wisniewski HM, Wegiel J. Beta-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol (Berl) 1994; 87: 233-241
50. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008; 131: 3299-3310
51. Ironside JW, Ghetti B, Head MW, Piccardo P, Will RG. Prion diseases. In Greenfield's Neuropathology. Eds SLD Love, DW Ellison. London: Hodder Arnold, 2009; 1197-1273
52. Gonzalez L, Martin S, Jeffrey M. Distinct profiles of PrP(d) immunoreactivity in the brain of scrapie- and BSE-infected sheep: implications for differential cell targeting and PrP processing. J Gen Virol 2003; 84: 1339-1350
53. Jeffrey M, McGovern G, Siso S, Gonzalez L. Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease. Acta Neuropathol (Berl) 2011; 121: 113-134
54. Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem 2009; 78: 177-204
55. Jeffrey M, Gonzalez L. Classical sheep transmissible spongiform encephalopathies: pathogenesis, pathological phenotypes and clinical disease. Neuropathol Appl Neurobiol 2007; 33: 373-394
56. Ghetti B, Piccardo P, Spillantini MG, Ichimiya Y, Porro M, Perini F, Kitamoto T, Tateishi J, Seiler C, Frangione B, Bugiani O, Giaccone G, Prelli F, Goedert M, Dlouhy SR, Tagliavini F. Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. Proc Natl Acad Sci U S A 1996; 93: 744-748
57. Jayadev S, Nochlin D, Poorkaj P, Steinbart EJ, Mastrianni JA, Montine TJ, Ghetti B, Schellenberg GD, Bird TD, Leverenz JB. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol 2011; 69: 712-720
58. Holton JL, Mead S, Gandhi S, Wadsworth JDF, Ayling H, Warren J, Lees AJ, Wood NW, Collinge J, Revesz T. Clinicopathological observations associated with a novel truncation mutation of PRNP. Neuropathol Appl Neurobiol 2010; 36 (Suppl. 1): 2-3
59. Jansen C, Parchi P, Capellari S, Vermeij AJ, Corrado P, Baas F, Strammiello R, van Gool WA, van Swieten JC, Rozemuller AJ. Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. Acta Neuropathol (Berl) 2010; 119: 189-197
60. Chesebro B, Race B, Meade-White K, Lacasse R, Race R, Klingeborn M, Striebel J, Dorward D, McGovern G, Jeffrey M. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog 2010; 6: e1000800
61. Jeffrey M, Goodsir CM, Holliman A, Higgins RJ, Bruce ME, McBride PA, Fraser JR. Determination of the frequency and distribution of vascular and parenchymal amyloid with polyclonal and N-terminal-specific PrP antibodies in scrapie-affected sheep and mice. Vet Rec 1998; 142: 534-537
62. Liberski PP, Guiroy DC, Williams ES, Walis A, Budka H. Deposition patterns of disease-associated prion protein in captive mule deer brains with chronic wasting disease. Acta Neuropathol (Berl) 2001; 102: 496-500
63. Rangel A, Race B, Striebel J, Chesebro B. Non-amyloid and amyloid prion protein deposits in prion-infected mice differ in blockage of interstitial brain fluid. Neuropathol Appl Neurobiol 2013; 39: 217-230
64. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 308: 1435-1439
65. Makarava N, Kovacs GG, Bocharova O, Savtchenko R, Alexeeva I, Budka H, Rohwer RG, Baskakov IV. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol (Berl) 2010; 119: 177-187
66. Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Budka H, Rohwer RG, Baskakov IV. Genesis of mammalian prions: from non-infectious amyloid fibrils to a transmissible prion disease. PLoS Pathog 2011; 7: e1002419
67. Makarava N, Kovacs GG, Savtchenko R, Alexeeva I, Ostapchenko VG, Budka H, Rohwer RG, Baskakov IV. A new mechanism for transmissible prion diseases. J Neurosci 2012; 32: 7345-7355
68. Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ. Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides 2002; 23: 1241-1247
69. Siso S, Jeffrey M, Gonzalez L. Neuroinvasion in sheep transmissible spongiform encephalopathies: the role of the haematogenous route. Neuropathol Appl Neurobiol 2009; 35: 232-246
70. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol 2009; 8: 643-653
71. Yamamoto Y, Craggs L, Baumann M, Kalimo H, Kalaria RN. Review: molecular genetics and pathology of hereditary small vessel diseases of the brain. Neuropathol Appl Neurobiol 2011; 37: 94-113
72. Low WC, Santa Y, Takahashi K, Tabira T, Kalaria RN. CADASIL-causing mutations do not alter Notch3 receptor processing and activation. Neuroreport 2006; 17: 945-949
73. Brulin P, Godfraind C, Leteurtre E, Ruchoux MM. Morphometric analysis of ultrastructural vascular changes in CADASIL: analysis of 50 skin biopsy specimens and pathogenic implications. Acta Neuropathol (Berl) 2002; 104: 241-248
74. Miao Q, Paloneva T, Tuominen S, Poyhonen M, Tuisku S, Viitanen M, Kalimo H. Fibrosis and stenosis of the long penetrating cerebral arteries: the cause of the white matter pathology in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Brain Pathol 2004; 14: 358-364
75. Dubroca C, Lacombe P, Domenga V, Maciazek J, Levy B, Tournier-Lasserve E, Joutel A, Henrion D. Impaired vascular mechanotransduction in a transgenic mouse model of CADASIL arteriopathy. Stroke 2005; 36: 113-117
76. Joutel A, Monet-Lepretre M, Gosele C, Baron-Menguy C, Hammes A, Schmidt S, Lemaire-Carrette B, Domenga V, Schedl A, Lacombe P, Hubner N. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest 2010; 120: 433-445
77. Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol 2010; 9: 309-317
78. Viswanathan A, Gray F, Bousser MG, Baudrimont M, Chabriat H. Cortical neuronal apoptosis in CADASIL. Stroke 2006; 37: 2690-2695
79. Tikka S, Mykkanen K, Ruchoux MM, Bergholm R, Junna M, Poyhonen M, Yki-Jarvinen H, Joutel A, Viitanen M, Baumann M, Kalimo H. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain 2009; 132: 933-939
80. Lewandowska E, Szpak GM, Wierzba-Bobrowicz T, Modzelewska J, Stepien T, Pasennik E, Schmidt-Sidor B, Rafalowska J. Capillary vessel wall in CADASIL angiopathy. Folia Neuropathol 2010; 48: 104-115
81. Arboleda-Velasquez JF, Manent J, Lee JH, Tikka S, Ospina C, Vanderburg CR, Frosch MP, Rodriguez-Falcon M, Villen J, Gygi S, Lopera F, Kalimo H, Moskowitz MA, Ayata C, Louvi A, Artavanis-Tsakonas S. Hypomorphic Notch 3 alleles link Notch signaling to ischemic cerebral small-vessel disease. Proc Natl Acad Sci U S A 2011; 108: E128-135
82. Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, Battail N, Piga N, Chapon F, Godfrain C, Tournier-Lasserve E. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 2000; 105: 597-605
83. Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N. Notch3 ectodomain is a major component of granular osmiophilic material (GOM) in CADASIL. Acta Neuropathol (Berl) 2006; 112: 333-339
84. Takahashi K, Adachi K, Yoshizaki K, Kunimoto S, Kalaria RN, Watanabe A. Mutations in NOTCH3 cause the formation and retention of aggregates in the endoplasmic reticulum, leading to impaired cell proliferation. Hum Mol Genet 2010; 19: 79-89
85. Unlu M, de Lange RP, de Silva R, Kalaria R, St Clair D. Detection of complement factor B in the cerebrospinal fluid of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy disease using two-dimensional gel electrophoresis and mass spectrometry. Neurosci Lett 2000; 282: 149-152
86. Palsdottir A, Snorradottir AO, Thorsteinsson L. Hereditary cystatin C amyloid angiopathy: genetic, clinical, and pathological aspects. Brain Pathol 2006; 16: 55-59